The American pharmaceutical company Novavax files an application for authorization of its anti-Covid vaccine in the European Union.
Last January, clinical trials of the two-dose Covid-19 vaccine of Novavax showed an efficacy of 89.3%, according to the American biotechnology company in a press release posting the results of the phase 3 trials.
"NVX-CoV2373 has the potential to play an important role in the resolution of this global public health crisis", then said the CEO of the company Stanley Erck.
At the time, the good news was offset by the joint announcement that the vaccine was much less effective against the variant identified first in South Africa (60%), which scientists consider to be more contagious. then immediately launched in the development of a new vaccine targeting this variant, said the press release.
Unlike the vaccines from Pfizer and Moderna, which use messenger RNA technology, the injection of the Novavax vaccine includes fragments of the coronavirus which make it possible to elicit an immune response in the human body.
Last August, Brussels announced a contract for the advance purchase of vaccines with Novavax.
On August 4, the European Commission announced that it had entered into a contract with the American pharmaceutical company Novavax for the advance purchase of 200 million doses of its vaccine once it has been approved by the European Medicines Agency (EMA). .
More information to come on 20minutes.fr ... / ...
Anti-covid vaccine
Coronavirus
Covid 19
Health
0 comment
0 share
Share on Messenger
Share on Facebook
Share on twitter
Share on Flipboard
Share on Pinterest
Share on Linkedin
Send by Mail
To safeguard
A fault ?
To print